ACRO BIOMEDICAL CO., LTD. is a Nevada-incorporated microcap company that, following a 2017 change of control, pivoted from its prior business to developing and marketing nutritional products focused on wellness. Historically, it acted primarily as a trading/distribution business: purchasing cordyceps-related supplements from three suppliers in Taiwan and reselling to a small number of distributors/customers, mainly in Taiwan and Hong Kong. The company has not generated any sales since December 31, 2022 and, as of its 2025 filings, reported no orders and no active marketing or distribution arrangements. Operations have been funded largely through advances from a minority stockholder, with substantial going-concern uncertainty disclosed in its reports.
0.04
0.04
| % | |
|---|---|
| Cordyceps-based supplements | 90% Cordyceps-related wellness products historically purchased from Taiwan suppliers and resold to distributors. |
| Other nutritional products (non-cordyceps) | 5% Non-cordyceps supplement items sold historically (e.g., metallothionein MT-3 elizer) and potential future complementary products. |
| R&D / product development initiatives | 0% Exploratory development work (e.g., chicken feed supplement concept) that has not resulted in commercial products. |
| Sourcing and distribution services (trading model) | 5% Supplier sourcing, import/fulfillment, and wholesale distribution activities supporting product resale. |
Historically, ACRO sold primarily to a very small number of unrelated distributor-type customers rather than directly...
Purchase cordyceps-related products for wholesale distribution and resale in Taiwan and adjacent markets.
Buy products for resale through Hong Kong-based channels with downstream exposure to PRC consumer demand and policy conditions.
Prospective channel partners needed to restart sales given the lack of current marketing and distribution arrangements.
The company is headquartered in Fishers, Indiana (United States) but historically sourced products from suppliers in...
Near-term strategy is constrained by the absence of orders, inventory purchases since 2022, and reliance on...
The company reports no current marketing/distribution arrangements and no orders, making channel development essential to restart revenue.
Operations have been funded primarily by advances from a minority stockholder and the company discloses substantial doubt about going concern.
A narrow product set increases sensitivity to changes in public tastes and category-specific demand shocks.
The dominant company-specific risk is going concern: ACRO has had no revenue since 2022, minimal cash, and relies on...
The company reports no revenues since December 31, 2022, minimal cash, and substantial doubt about continuing as a going concern.
Primary financing has been advances from a minority stockholder (and to a lesser extent the CEO) with no assurance of continuation.
Two customers represented 100% of 2022 revenue and 91.7% of 2021 revenue; customers can cease purchasing at any time.
Each country has laws on purity, labeling, and approvals; inability to comply can block sales or trigger enforcement actions.
Management cites impacts from China’s COVID-19 restrictions and political/legal situation in Hong Kong on sales and fundraising.
No long-term supplier agreements and potential interruptions (transport, disasters) can raise costs or limit availability.
The company discloses it does not have product liability insurance, increasing financial impact of any claims.
ADVB · Services-Medical Laboratories
BICX · Services-Specialty Outpatient Facilities, NEC
BIVI · Pharmaceutical Preparations
CERO · Biological Products, (No Diagnostic Substances)
AARD · Pharmaceutical Preparations
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
: 11/08/2026